Search Results - Bennet, Jillian K.

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

    Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomise... by Chappell, Keith J., Mordant, Francesca L., Amarilla, Alberto A., Modhiran, Naphak, Liang, Benjamin, Li, Zheyi, Wijesundara, Danushka K., Lackenby, Julia A., Griffin, Paul, Bennet, Jillian K., Hensen, Luca, Zhang, Wuji, Nguyen, Thi H.O., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Kedzierska, Katherine, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R., Munro, Trent P.

    Published in EBioMedicine
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialResearch in context

    Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomise... by Keith J. Chappell, Francesca L. Mordant, Alberto A. Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Danushka K. Wijesundara, Julia A. Lackenby, Paul Griffin, Jillian K. Bennet, Luca Hensen, Wuji Zhang, Thi H.O. Nguyen, Mai H. Tran, Peter Tapley, James Barnes, Patrick C. Reading, Katherine Kedzierska, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R. Young, Trent P. Munro

    Published in EBioMedicine
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

    Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial by Chappell, Keith J, Mordant, Francesca L, Li, Zheyi, Wijesundara, Danushka K, Ellenberg, Paula, Lackenby, Julia A, Cheung, Stacey T M, Modhiran, Naphak, Avumegah, Michael S, Henderson, Christina L, Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H O, Marrero-Hernandez, Sara, Selva, Kevin J, Chung, Amy W, Tran, Mai H, Tapley, Peter, Barnes, James, Reading, Patrick C, Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D, Hogarth, P Mark, Kedzierska, Katherine, Purcell, Damian F J, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R, Munro, Trent P

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: